Should I buy, hold, or sell TIL stock right now?

Instil Bio Inc. (TIL) currently earns a Roarable Rating of D- (Sell — SELL) with 39/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is TIL's 12-month price target and RQD AI Jury consensus?

TIL's 12-month base price target is $6.22 (range $4.85 to $18.49), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / TIL

IMA (19) LONA (35) CRBU (32) INMB (30) ⌘ Pro Terminal →

Instil Bio Inc. (TIL) — RQD Stock Rating Cockpit

$6.80 -0.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.78

Instil Bio Inc. (TIL) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $46.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TIL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TIL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Instil Bio Inc. (NASDAQ: TIL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.80 (-0.37% 1D, market cap $46.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TIL ranks #488 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TIL compare to IMA and LONA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TIL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMA (ImageneBio Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M) and LONA (LeonaBio Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.5M). Among the 5-stock peer group, TIL leads on earnings multiple (N/A) while TIL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TIL?

▼

Per TIL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789769), Instil Bio Inc. generated $220.0M in revenue (+6.9% YoY), -$71.4M in net income, and -$36.6M in free cash flow against $203.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.78 (-0.26%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TIL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY TIL SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.18-3.9% Next Q

Q2 (-2Q)

Grade E$5.94-1.7% Next Q

Q3 (-1Q)

Grade E$5.84+16.4% Next Q

Current

Grade D-$6.80-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TIL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TIL currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.93) and Max Pain ($7.14) forces dealer call-delta covering toward $18.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TIL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TIL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

56.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE10% OF RANGE

L: $6$6.80H: $18

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on TIL

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (33)

12/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like TIL

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TIL)

✓Walkthrough of TIL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TIL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.27%▼ DESCENDING CHANNEL

2026-11-03O $6.82H $6.82L $6.80C $6.80VOL 25.2K

RES: $7.52SUP: $5.47SMA50: $6.93SMA200: $7.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TIL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TIL Butterfly Map → + Track TIL →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +6.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TIL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TIL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TIL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TIL)

Health Care Rank #488 of 1015 ⚔️ IMA vs TIL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TIL vs. IMA, LONA, CRBU, INMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Instil Bio Inc. (TIL) ranks #488 by composite RQD confidence (39/100, grade D-) and #758 by equity capitalization ($46.1M). Within this direct 5-issuer industry benchmark cohort, TIL leads on earnings valuation at N/A trailing P/E, while TIL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently leads its immediate peer cohort in composite quantitative strength at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TIL ACTIVE Instil Bio Inc.	D-	39/100	—	—	-35.0%	-0.37%	$46.1M	Benchmark Subject
IMA ImageneBio Inc.	E	19/100	—	—	-35.0%	+1.24%	$46.5M	/ima-vs-til →
LONA LeonaBio Inc.	D-	35/100	—	—	-35.0%	+0.61%	$46.5M	/lona-vs-til →
CRBU Caribou Biosciences Inc.	E	32/100	—	—	-35.0%	-4.90%	$45.4M	/crbu-vs-til →
INMB INmune Bio Inc.	E	30/100	—	—	-35.0%	-9.37%	$44.9M	/inmb-vs-til →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001789769 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Instil Bio Inc. (TIL) reported GAAP revenue of $220.0M (+6.9% vs. FY2024 revenue of $205.9M , and -50.6% cumulative change since FY2023) , GAAP net income of -$71.4M, operating cash flow of -$36.6M, and free cash flow of -$36.6M (+34.3% YoY). On the balance sheet, TIL closed FY2025 with $203.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$220.0M	-$71.4M	-$36.6M	-$36.6M	$203.5M	—
FY2024 (FY)	2024-12-31	$205.9M	-$74.1M	-$55.7M	-$55.7M	$263.6M	—
FY2023 (FY)	2023-12-31	$445.7M	-$156.1M	-$82.0M	-$82.0M	—	—

3. TIL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TIL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TIL compare to IMA and LONA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TIL?

Where is TIL trading relative to its 50-day, 200-day, and 52-week technical levels?

TIL last traded at $6.80 (-0.37% on volume of 25,233 shares), positioning the stock -1.88% below its 50-day simple moving average ($6.93) and -11.46% below its 200-day simple moving average ($7.68). Across its 52-week range of $5.56 to $17.61, TIL sits at the 10.3% percentile with a 14-day RSI of 56.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.95 to $7.65).

Direct Sub-Reports: TIL RQD Cockpit TIL 12M Forecast TIL Earnings & Move TIL Dividends & DRIP TIL Insiders & 13F TIL Whale Options TIL Profit Sankey TIL News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

TIL — Instil Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Instil Bio Inc. (TIL) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.80 (-0.37% 1D, market capitalization $46.1M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Instil Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. The FY 2025 and FY 2024 financials report — in revenue, which is the only available indication of commercial activity in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Instil Bio Inc. (TIL) reported $220.0M in annual revenue (up from $205.9M in FY2024, +6.9% YoY) and -$71.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($445.7M revenue, -$156.1M net income) through FY2025, TIL scaled operating cash flow to -$36.6M and free cash flow to -$36.6M, backed by $203.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $5.56 – $17.61 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note the absence of mapped links means this analysis cannot identify specific supplier, customer, or partner exposure.

Key Question #1: Can TIL sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $220.0M and free cash flow of -$36.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is TIL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TIL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Instil Bio Inc. (TIL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TIL Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 22h ago

Instil Bio, Inc. Estimates – NASDAQ:TIL

TradingView report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.siam.in • 1d ago

Instil Bio (TIL) Edges Lower: Shares Slip 1.47% to $5.70 as Traders Watch $5.42 Support - Key Reversal Day

www.siam.in report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Liquidity Mapping Around (TIL) Price Events

Stock Traders Daily report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Instil Bio (TIL) Ticks Higher to $5.84 as Buyers Test Upper Range - Stock Buy Zone

https://www.dars.gov.et/ report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Unusual Volume Stocks & Volume Spikes Today

TradingKey report covering Instil Bio Inc. (TIL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TIL Bull vs. Bear Conversation Board — What's Your Call at $6.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TIL 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $8.43 (+24.0%)

📌 Pinned Debate

Net losses narrowed from -$156.1M in FY 2023 to -$71.4M in FY 2025 while the stock trades near the low end of its $5.56 - $18.13 52-wee

Here is why I am bullish on TIL here at $6.80: Net losses narrowed from -$156.1M in FY 2023 to -$71.4M in FY 2025 while the stock trades near the low end of its $5.56 - $18.13 52-week range.. Compare TIL's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $6.46 are getting bought.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 7/20 institutional whale-flow stock at $6.80 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $5.44 (-20.0%)

Spot @ $6.80

Zero reported revenue, FCF of -$36.6M against $6.6M of cash, and a 39 RQD score with a D- grade signal a vulnerable balance sheet and w

Zero reported revenue, FCF of -$36.6M against $6.6M of cash, and a 39 RQD score with a D- grade signal a vulnerable balance sheet and weak flow.. Look at the math on TIL: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $5.98 before getting long.